Two recent studies have reported that COVID boosters can increase the humoral response in MS patients during treatment with ocrelizumab or fingolimod. A number of studies have reported that these disease-modifying therapies (DMT) are associated with a blunted humoral response to COVID vaccination (Achiron et al. Ther Adv Neurol Disord 2021;14:17562864211012835. Gallo et al. Neurol Sci 2021;42:3523-3526). Read More
COVID-19
ECTRIMS 2022 HIGHLIGHTS – SATURDAY, OCTOBER 29 EDITION
October 29, 202238th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 26-28, 2022
The following summarizes some of the highlights from Day 3 of ECTRIMS 2022.
ECTRIMS 2022 HIGHLIGHTS – THURSDAY, OCTOBER 27 EDITION
October 27, 202238th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 26-28, 2022
The following summarizes some of the highlights from Day 1 of ECTRIMS 2022.
Bivalent COVID booster approved in Canada
September 16, 2022In September, Health Canada approved the use of a first-generation bivalent booster vaccine against the SARS CoV-2 virus for use in adults aged >18 years (www.canada.ca/en/health-canada/news/2022/09/health-canada-authorizes-first-bivalent-covid-19-booster-for-adults-18-years-and-older.html). Read More
COVID-19 and MS – updated findings
July 28, 2022The following is a summary of recent findings on COVID-related issues in patients with multiple sclerosis. Read More